<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859598</url>
  </required_header>
  <id_info>
    <org_study_id>ORBIT</org_study_id>
    <nct_id>NCT01859598</nct_id>
  </id_info>
  <brief_title>Observational Registry for Basal Insulin Treatment Study (ORBIT)</brief_title>
  <official_title>A Prospective, Observational Registry Study Focusing on the Real World Use, Effectiveness and Safety of Initial Basal Insulin Regimen in Type 2 Diabetic Patients Uncontrolled by Oral Antidiabetic Drugs in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute for Global Health, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Diabetes Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute for Global Health, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scientific use of basal insulin is of great help to individuals and the government.
      However, there are few studies to investigate the real world use, effect, safety and
      influence factors of basal insulin in China. This study is to evaluate the use of first basal
      insulin in China patients with type 2 diabetes with inadequate glycemic control on oral
      antidiabetic agents (OADs) from the naturalistic clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6-month multicentre, observational, prospective, registry study. About 200
      hospitals from different parts of China will take part in this study, and about 20,000
      patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with OADs and
      willing to accept basal insulin (BI) treatment will be consecutively enrolled during a 12
      months period.

      The study participants will include at baseline (0 month), 3 month and end point (6 month) to
      collect the study information. The project will probably last for about 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>To Assess the Change in HbA1c During the 6 Months Follow-up.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>• Change of HbA1c from baseline to the end-point (6 month).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the Change of Hypoglycemia During Follow-up.</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>•The rate of hypoglycemia at baseline, 3 months (visit 2) and 6 months (visit 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the FPG Change From Visit 1 to Visit 3</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>the FPG change = the FPG level at visit 1- the FPG level at visit 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the FPG Control Rate at Visit 3</measure>
    <time_frame>6 months</time_frame>
    <description>the percentage of patients who had the FPG level &lt;7.0 mmol/L at visit 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Weight Gain From Visit 1 to Visit 3</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>the weight gain= the mean weight at visit1 - the mean weight at visit 3</description>
  </secondary_outcome>
  <enrollment type="Actual">19894</enrollment>
  <condition>Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients meet the following criteria, either from in-patient or out-patient department,
        will have chance to be enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old

          -  Type 2 diabetic patients

          -  Taking OADs before inclusion

          -  Recently tested HbA1c &gt;=7% at the same site within 3 months

          -  Being suggested by physician to start basal insulin (BI) treatment

          -  Willing to start and having been prescribed BI treatment

          -  Willing to join the registry study and sign the informed consent

        Exclusion Criteria:

          -  Diagnosed with type 1 diabetes

          -  Received any type of insulin in the last 2 years (except for the intermittent use of
             insulin of less than 1 month each time)

          -  With any severe health problem, or any other situation judged by the investigator,
             that is difficult for the 6 months follow-up

          -  Current or planned pregnant, lactating women

          -  Involved in other clinical trial simultaneously or at most 1 month before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linong Ji, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute for Global Health, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haidian hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <results_first_submitted>February 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2016</results_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>basal insulin</keyword>
  <keyword>effectiveness and safety</keyword>
  <keyword>oral antidiabetic drugs</keyword>
  <keyword>real world clinical practice</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From December of 2011 to June 2013 in secondary and tertiary hospitals all over China, including in-patients and out-patients.</recruitment_details>
      <pre_assignment_details>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>6-month Follow-up for Basal Insulin Treatment Study (ORBIT)</title>
          <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 2 at 3 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18995">At visit 1, patients remained at baseline, N=18995</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1742"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1742"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 3 at 6 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16341">Loss to follow-up, N=1517; Come back at visit 3, N=605;</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="912"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Follow up for 6 Months</title>
          <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18995"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c level</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG) level</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary school or illiterate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Complication</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.1" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (DBP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recruitment settings</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Out-patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospital levels</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Secondary hospitals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertiary hospitals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current residence of patients</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Urban</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rural</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-insulin hypoglycemia</title>
          <units>times/person/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical activity</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Change in HbA1c During the 6 Months Follow-up.</title>
        <description>• Change of HbA1c from baseline to the end-point (6 month).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>the patients who have the results of HbA1c</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Insulin Treatment Study (ORBIT)</title>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Change in HbA1c During the 6 Months Follow-up.</title>
          <description>• Change of HbA1c from baseline to the end-point (6 month).</description>
          <population>the patients who have the results of HbA1c</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>the Change of Hypoglycemia During Follow-up.</title>
        <description>•The rate of hypoglycemia at baseline, 3 months (visit 2) and 6 months (visit 3)</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>The population at visit 3 were used to analyze the hypoglycemia and weight change from visit 1 to visit 3</population>
        <group_list>
          <group group_id="O1">
            <title>Follow up for 6 Months</title>
            <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);
At visit 1: Patients remained at baseline, N=18995; Loss to follow-up, N=1742 At visit 2, N=17253; Come back at visit 3, N=605 Loss to follow-up, N=1517 At visit 3, N=16341</description>
          </group>
        </group_list>
        <measure>
          <title>the Change of Hypoglycemia During Follow-up.</title>
          <description>•The rate of hypoglycemia at baseline, 3 months (visit 2) and 6 months (visit 3)</description>
          <population>The population at visit 3 were used to analyze the hypoglycemia and weight change from visit 1 to visit 3</population>
          <units>percentage of patients with hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the FPG Change From Visit 1 to Visit 3</title>
        <description>the FPG change = the FPG level at visit 1- the FPG level at visit 3</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>the population in the visit 3 were used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Follow up for 6 Months</title>
            <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);
At visit 1: Patients remained at baseline, N=18995; Loss to follow-up, N=1742 At visit 2, N=17253; Come back at visit 3, N=605 Loss to follow-up, N=1517 At visit 3, N=16341</description>
          </group>
        </group_list>
        <measure>
          <title>the FPG Change From Visit 1 to Visit 3</title>
          <description>the FPG change = the FPG level at visit 1- the FPG level at visit 3</description>
          <population>the population in the visit 3 were used for analysis</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the FPG Control Rate at Visit 3</title>
        <description>the percentage of patients who had the FPG level &lt;7.0 mmol/L at visit 3</description>
        <time_frame>6 months</time_frame>
        <population>At visit 3, the patients who self-reported their FPG level were used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Follow up for 6 Months</title>
            <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);
At visit 1: Patients remained at baseline, N=18995; Loss to follow-up, N=1742 At visit 2, N=17253; Come back at visit 3, N=605 Loss to follow-up, N=1517 At visit 3, N=16341, among them, 10416 patients had FPG information</description>
          </group>
        </group_list>
        <measure>
          <title>the FPG Control Rate at Visit 3</title>
          <description>the percentage of patients who had the FPG level &lt;7.0 mmol/L at visit 3</description>
          <population>At visit 3, the patients who self-reported their FPG level were used for analysis</population>
          <units>percentage of patients with FPG&lt;7.0</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Weight Gain From Visit 1 to Visit 3</title>
        <description>the weight gain= the mean weight at visit1 - the mean weight at visit 3</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>Patients at visit 3 were used for analyzing the change of weight</population>
        <group_list>
          <group group_id="O1">
            <title>Follow up for 6 Months</title>
            <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);
At visit 1: Patients remained at baseline, N=18995; Loss to follow-up, N=1742 At visit 2, N=17253; Come back at visit 3, N=605 Loss to follow-up, N=1517 At visit 3, N=16341, among them, 10416 patients had FPG information</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Weight Gain From Visit 1 to Visit 3</title>
          <description>the weight gain= the mean weight at visit1 - the mean weight at visit 3</description>
          <population>Patients at visit 3 were used for analyzing the change of weight</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to 6 months</time_frame>
      <desc>Led to death; Resulted in a life-threatening illness or injury; Required in-patient hospitalization or prolongation of existing hospitalization; Resulted in permanent impairment of a body structure or function; Led to congenital abnormality or birth defect. Resulted in important medical event or reaction</desc>
      <group_list>
        <group group_id="E1">
          <title>Follow up for 6 Months</title>
          <description>At the baseline stage:
Patients registered to assess the eligibility(N=19894); Violate inclusion criteria (N=346); Excluded (N=553);
At visit 1: Patients remained at baseline, N=18995; Loss to follow-up, N=1742 At visit 2, N=17253; Come back at visit 3, N=605 Loss to follow-up, N=1517 At visit 3, N=16341</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="635" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-cerebrovascular disease</sub_title>
                <counts group_id="E1" events="258" subjects_affected="258" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye disease</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disease</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nerve system</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephroma</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary disease</sub_title>
                <counts group_id="E1" events="103" subjects_affected="103" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18995"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The characteristics of patients receiving different treatment modalities may not be consistent, and the use of Basal Insulin (BI) depended on individual choices of doctors and patients, resulting in differences in insulin usage among various regions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pro. Linong Ji</name_or_title>
      <organization>The George Institute for Global Health at Peking University Health Science Center</organization>
      <phone>82800577</phone>
      <email>jiln@bjmu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

